Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007

Wednesday, October 31, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

BETHESDA, Md., Oct. 31 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammation andautoimmune diseases, today announced that Dr. Christian Itin, President andChief Executive Officer of Micromet, will present at the Acumen BioFin Rodman& Renshaw 9th Annual Healthcare Conference in New York, on Wednesday, November7, 2007 at 9:50am Eastern Time (3:50pm Central European Time).

An audio webcast of Dr. Itin's remarks will be available live andaccessible through Micromet's website at www.micromet-inc.com, as well as areplay and download of the presentation slides following the event.

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the developmentof novel, proprietary antibodies for the treatment of cancer, inflammation andautoimmune diseases. Three of its antibodies are in clinical development.MT103 (MEDI-538), the first antibody developed using the BiTE(R) technologyplatform to be clinically validated in Micromet's product pipeline, is beingevaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies thatactivate a patient's own cytotoxic T cells to eliminate cancer cells.Micromet is developing MT103 in collaboration with MedImmune, a subsidiary ofAstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201),a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumabis being developed by Micromet in collaboration with Merck Serono, a divisionof Merck KGaA in Darmstadt, Germany, in a phase 1b clinical trial evaluatingMT201 in combination with docetaxel for the treatment of patients withmetastatic breast cancer. The third clinical stage antibody is MT293(formerly D93); also known as TRC093, a first-in-class humanized monoclonalantibody that inhibits angiogenesis and tumor cell growth by binding cleavedcollagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is beingdeveloped in a phase 1 clinical trial for the treatment of patients withcancer and age-related macular degeneration. In addition, Micromet hasestablished a collaboration with Nycomed for the development andcommercialization of MT203, Micromet's human antibody neutralizing theactivity of GM-CSF, which has potential applications in the treatment ofinflammatory diseases, such as rheumatoid arthritis, as well as autoimmunediseases.

SOURCE Micromet, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook